STARx
LNP/mRNA platform that targets disease-causing Th17 cells in vivo
Community-submitted · content unverified. This organization has not verified ownership or the information in this profile.
About
STARx is one of ai3Bio's two public therapeutic platforms for autoimmune disease. According to the company's September 2026 launch materials, STARx uses a lipid nanoparticle to deliver mRNA that triggers a targeted self-destruct process in pathogenic Th17 cells in vivo, aiming for a one-step immune reset complementary to the antibody-based T Deplete platform.
- Website
- ai3.bio/starx
- Added via
- web
- Ownership
- unclaimed
Where to go
Product details
- Product kind
- Other